New York State is appealing a state trial court’s dismissal of its antitrust case against CVS Health that alleges the pharmacy giant unlawfully forces 340B covered entities to use its 340B third party administrator Wellpartner in order to contract with
…
The U.S. Department of Health and Human Services and the Health Resources and Services Administration “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution process, the government said in a recent legal filing.
The government
…
The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal
…
Arkansas’ 340B contract pharmacy law, for now the only state law of its kind, has no place in the federal 340B “closed system,” Pharmaceutical Research and Manufacturers of America (PhRMA) recently told a federal appeals court.
“340B is a closed
…
A once-dead lawsuit that accuses drug makers of colluding to deny 340B pricing on insulin and diabetes drugs shipped to contract pharmacies is going to be heard July 20 in federal district court in Rochester, N.Y.
Chief Judge Elizabeth Wolford
…
A federal district judge last week declined to make federal health officials give a South Carolina health center any more documents linked to the center’s brief expulsion from and subsequent reinstatement to the 340B program in 2018.
U.S. Chief District
…
Three groups representing 340B hospitals late last week filed an amicus brief in federal circuit court in support of Arkansas’ novel contract pharmacy law, arguing the law doesn’t conflict with the 340B statute and in fact furthers the goals of
…
A Philadelphia-area hospital that closed last year after its sale fell through has filed a federal antitrust class action against healthcare conglomerate CVS over its 340B contract pharmacy policies.
The same shuttered hospital has been challenging in state court its
…
The federal government yesterday decided not to ask all 14 judges on the U.S. Third Circuit Court of Appeals in Philadelphia to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when
…*Sign up for news summaries and alerts from 340B Report